{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:40:03Z","timestamp":1754163603467,"version":"3.41.2"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>The management of uterine leiomyosarcomas (uLMS) remains challenging. The rate of recurrence and metastasis is high, with 5-yr survival reaching only 40% to 50% in patients with tumor confined to the uterus (FIGO stage I or II). Prolactin receptor (PRLR) and growth hormone-releasing hormone receptor (GHRHR) have been implicated in the carcinogenesis of malignant tumors of the breast, endometrium, ovary, liver, and prostate. GHRHR antagonists inhibit <jats:italic toggle=\"yes\">in vitro<\/jats:italic> growth of many human tumors and the expression of PRLR is associated with resistance to chemotherapy. The immunohistochemical expression of PRLR and GHRH in 24 primary and 2 recurrent uLMS was evaluated. Representative sections were stained with PRLR and GHRHR antibodies and immunoreactivity was calculated using <jats:italic toggle=\"yes\">H<\/jats:italic>-score. The results were correlated with clinicopathologic data using Kaplan-Meier survival and multivariable Cox proportion hazard regression analyses. All tumors were positive for both markers with predominantly moderate to strong expression of PRLR (89%) and GHRHR (82%). Patients with tumors showing moderate to strong expression of PRLR were significantly less likely to achieve disease-free survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.004) and significantly more likely to have a poor overall survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.049). No significant difference in mean PRLR expression was found between tumors with higher mitotic counts (&gt;20\/10 hpf) and lower mitotic counts (20 or less\/10 hpf). Furthermore, in 2 patients where the primary and recurrent tumors were tested, there was stronger expression of PRLR in the recurrence compared with the primary. This correlation was not found with GHRHR. Both PRLR and GHRHR may play a role in carcinogenesis in uLMS, as they do in other malignant neoplasms. To our knowledge, this study is the first evaluating the expression of these receptors in uLMS. Moderate or high expression of PRLR may serve as a prognostic marker associated with recurrences and increased mortality in uLMS patients.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000844","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T18:02:05Z","timestamp":1638468125000},"page":"566-572","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Potential Prognostic and Therapeutic Implications of Prolactin Receptor and Growth Hormone-releasing Hormone Receptor Expression in Uterine Leiomyosarcomas"],"prefix":"10.1097","volume":"41","author":[{"given":"Terri E.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae-Sun","family":"La","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swikrity","family":"Upadhyay-Baskota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirka W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"issue":"suppl","key":"R2-20250802","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00000478-199406000-00001","article-title":"Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases","volume":"18","author":"Bell","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/IGC.0000000000000372","article-title":"Trends in the treatment of uterine leiomyosarcoma in the medicare population","volume":"25","author":"Foley","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/PAS.0000000000001254","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes in uterine smooth muscle tumors: implications for immunotherapy","volume":"43","author":"Shanes","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41379-019-0202-3","article-title":"Characteristics of mismatch repair deficiency in sarcomas","volume":"32","author":"Doyle","year":"2019","journal-title":"Mod Pathol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12253-014-9814-6","article-title":"Prolactin and prolactin receptor expression in cervical intraepithelial neoplasia and cancer","volume":"21","author":"Ascencio-Cedillo","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2017.05.009","article-title":"Prolactin receptor targeting in breast and prostate cancers: new insights into an old challenge","volume":"179","author":"Goffin","year":"2017","journal-title":"Pharmacol Ther"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAI.0000000000000622","article-title":"Expression of GHRH-R, a potentially targetable biomarker, in triple-negative breast cancer","volume":"26","author":"Khanlari","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"17424","DOI":"10.1073\/pnas.0506844102","article-title":"The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues","volume":"102","author":"Havt","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bjh.15207","article-title":"A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone","volume":"181","author":"Jimenez","year":"2018","journal-title":"Br J Haematol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"djv338","DOI":"10.1093\/jnci\/djv338","article-title":"The role of prolactin in bone metastasis and breast cancer cell-mediated osteoclast differentiation","volume":"108","author":"Sutherland","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/JME-16-0150","article-title":"Prolactin receptor in breast cancer: marker for metastatic risk","volume":"57","author":"Shemanko","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/PAI.0000000000000178","article-title":"Prolactin receptor expression is an independent favorable prognostic marker in human breast cancer","volume":"24","author":"Hachim","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-013-0165-7","article-title":"Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland","volume":"5","author":"Faupel-Badger","year":"2014","journal-title":"Horm Cancer"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/modpathol.2010.83","article-title":"Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases","volume":"23","author":"Harbaum","year":"2010","journal-title":"Mod Pathol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ijbiomac.2016.11.015","article-title":"Development of a new anti-prolactin receptor (PRLR) antibody, F56, which can serve as a PRLR antagonist","volume":"95","author":"Cui","year":"2017","journal-title":"Int J Biol Macromol"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1634\/theoncologist.2015-0502","article-title":"Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer","volume":"21","author":"Agarwal","year":"2016","journal-title":"Oncologist"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s10637-020-00960-z","article-title":"A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors","volume":"38","author":"Lemech","year":"2020","journal-title":"Invest New Drugs"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"594370","DOI":"10.3389\/fendo.2020.594370","article-title":"The interplay between prolactin and reproductive system: focus on uterine pathophysiology","volume":"11","author":"Auriemma","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000010154","article-title":"Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells","volume":"48","author":"Nowak","year":"1999","journal-title":"Gynecol Obstet Invest"},{"key":"R28-20250802","first-page":"582","article-title":"Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers","volume":"84","author":"Kah\u00e1n","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0015-0282(00)01658-7","article-title":"Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions","volume":"75","author":"Khorram","year":"2001","journal-title":"Fertil Steril"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/pros.23648","article-title":"Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer","volume":"78","author":"Mu\u00f1oz-Moreno","year":"2018","journal-title":"Prostate"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1073\/pnas.1818865116","article-title":"Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma","volume":"116","author":"Villanova","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"14745","DOI":"10.1073\/pnas.1618582114","article-title":"Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3\/NF-\u03baB signaling","volume":"113","author":"Gan","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:03:38Z","timestamp":1754161418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000844","relation":{},"ISSN":["0277-1691"],"issn-type":[{"type":"print","value":"0277-1691"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}